Net Pals Net Pals
Résultats de Recherche
Voir tous les résulats
  • Nous rejoindre
    Se connecter
    S’enregistrer
    Rechercher
    Mode nuit

Rechercher

Découvrez de nouvelles personnes, créer de nouvelles connexions et faire de nouveaux amis

  • Fil d’actualités
  • EXPLORER
  • Pages
  • Groupes
  • Evènements
  • Reels
  • Blogs
  • Marketplace
  • Offres
  • Emplois
  • Articles
  • Blogs
  • Utilisateurs
  • Pages
  • Groupes
  • Evènements
  • JamesWilson Ajouter une nouvelle offre d'emploi Autre
    2026-10-23 19:43:53 - Traduire -
    Ionis (IONS) partner Roche shows sefaxersen cut IgA nephropathy proteinuria 43.1% in Phase 3
    Roche gave the first effect size from its IMAgINATION kidney trial at ASN Kidney Week, a clearer read for Ionis Pharmaceuticals Inc. (IONS) on a partnered drug that carries milestones and royalties. Sefaxersen cut proteinuria by 43.1% against placebo at 37 weeks in a Phase 3 trial in IgA nephropathy, according to data Ionis Pharmaceuticals Inc. (IONS) released on October 23. Roche Holding AG,...
    0 Commentaires 0 Parts 8 Vue 0 Aperçu
    Connectez-vous pour aimer, partager et commenter!
  • JasonWilliams Ajouter une nouvelle offre d'emploi Autre
    2026-10-23 15:43:10 - Traduire -
    Rithm Capital (RITM) distributable earnings slip to $0.55 a share as Newrez lending volume falls 19%
    Rithm Capital Corp. (RITM) posted much higher GAAP profit on a swing in mortgage servicing values, but its non-GAAP earnings measure fell as funded mortgage volume dropped from the second quarter. Newrez funded $12.9 billion of mortgages in the third quarter, 19% less than in the second quarter and 21% less than a year earlier. Rithm Capital Corp. (RITM) disclosed the figure in its results for...
    0 Commentaires 0 Parts 7 Vue 0 Aperçu
    Connectez-vous pour aimer, partager et commenter!
© 2026 Net Pals French
English Arabic French Spanish Portuguese Deutsch Turkish Dutch Italiano Russian Romaian Portuguese (Brazil) Greek
Environ Conditions générale de vente Confidentialité Cookies Acceptable Use Contactez nous Annuaire